This conference will highlight different approaches to bispecific antibody constructs and reveal key elements for efficacy and drug-like properties. Disease areas beyond oncology will be reviewed, such as ophthalmology, infectious disease, and inflammatory diseases. Aspects for enhancement such as purification, stability, neutralization, enhanced targeting, modulating immune response, expression, characterization, improvements in humanization and clearance will be considered.
KEYNOTE PRESENTATION: Creating a Wide Variety of Nanoparticles, Antibody-Drug Conjugates and Bispecific Antibodies
Ulrich B. Nielsen, Ph.D., CSO & Senior Vice President, Merrimack Pharmaceuticals
Talk Title to be Announced
Trevor J. Hallam, Ph.D., CSO, Sutro Biopharma
New Platform for scFv-Based Bispecifics
G. Jonah Rainey, Ph.D., Senior Scientist, ADPE, MedImmune, LLC
High-Throughput Design, Production, and Evaluation of Bispecific Antibodies
Maria Wendt, Ph.D., Senior Scientific Consultant, Biologics, Genedata
A Novel Platform for Engineering Blood-Brain Barrier-Crossing Bispecific Biologics
Graham Farrington, Ph.D., Director, Protein & Antibody Engineering, Biogen
Functional Characterization of Blood-Brain Barrier-Crossing Antibodies
Danica B. Stanimirovic, M.D., Ph.D., Director, R&D, Translational Bioscience, Human Health Therapeutics Portfolio, National Research Council of Canada
Recent BBB Transport Efforts in Cyno Using an Affinity Engineered Anti-Tfr/BACE1 Bispecific
Mark S. Dennis, Ph.D., Principal Scientist, Genentech, Inc.
Many Birds, One Stone: Discovering Multi-Specific mAbs for Infectious Diseases
Eszter Nagy, M.D., Ph.D., CSO, President, Arsanis, Inc.
Anti-Infective Bispecific Antibodies for Viral Infections
Paul MacAry, Ph.D., Associate Professor, Microbiology, National University of Singapore
FIT-Ig: A Novel Bispecific Antibody Format Combining Any Two mAbs into One Bi-Functional Ig Molecule
Robert Kamen, Ph.D., Epimab Biotherapeutics
Designing and Discovering Transformative Bispecific Antibody Therapeutics
Martin Steegmaier, Ph.D., MBA, Head, Discovery, Large Molecule Research & Early Development (pRED), Roche Innovation Center Penzberg GmbH
Bispecific Fynomabs: Novel Mode-of-Action through Tailored Architecture
Simon Brack, Ph.D., Director, Discovery Research, Covagen AG
Facile Generation of Common Light Chain Bispecific Antibodies
Eric M. Krauland, Ph.D., Senior Director, Antibody Discovery and Optimization, Adimab LLC
Bispecific Antibodies against HIV-1 and Cancer-Related Proteins
Dimiter S. Dimitrov, Ph.D., Senior Investigator, Experimental Immunology Laboratory, National Cancer Institute, NIH
T Cell Engaging Technology
Annelise Vuidepot, Ph.D., Head, Protein Science, Immunocore Ltd.
Optimization and Application of an Fc-Containing Bispecific Platform
John R. Desjarlais, Ph.D., CSO, Xencor, Inc.
Talk Title to be Announced
Carlo Boutton, Ph.D., Director, Technology & Information Management, Ablynx nv